Impact News +++ The Nomination Committee′s proposal for the Board of Directors of MilDef Group (Cision) +++ MILDEF Aktie -3,59%

CYPHERPUNK Aktie

>CYPHERPUNK Aktienkurs

0.65 EUR +4.0% (TradegateBSX)

Ask: 0.645 EUR / 3000 Stück

Bid: 0.555 EUR / 3000 Stück

Tagesumsatz: 6000 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CYPHERPUNK Aktie über LYNX handeln

Intraday

1 Jahr

>CYPHERPUNK Performance

1 Woche: +21,9%

1 Monat: -4,0%

3 Monate: -42,8%

6 Monate: +122,8%

1 Jahr: +66,2%

laufendes Jahr: -43,9%

>CYPHERPUNK Aktie

Name:

CYPHERPUNK TECHNOLOGIES

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US52187K2006 / A3EMJP

Symbol/ Ticker:

5MC (Frankfurt) / CYPH (NASDAQ)

Kürzel:

FRA:5MC, ETR:5MC, 5MC:GR, NASDAQ:CYPH

Index:

Webseite:

https://www.leaptx.com/

Profil:

Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company..
>Volltext..

Marktkapitalisierung:

28.78 Mio. EUR

Unternehmenswert:

20.49 Mio. EUR

Umsatz:

EBITDA:

-41.66 Mio. EUR

Nettogewinn:

-44.51 Mio. EUR

Gewinn je Aktie:

-1.08 EUR

Schulden:

0.03 Mio. EUR

Liquide Mittel:

8.48 Mio. EUR

Operativer Cashflow:

-46.24 Mio. EUR

Bargeldquote:

1.11

Umsatzwachstum:

Gewinnwachstum:

25.35%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CYPHERPUNK, LEAP THERAPEUTICS

Letzte Datenerhebung:

17.03.26

>CYPHERPUNK Kennzahlen

Aktien/ Unternehmen:

Aktien: 56.65 Mio. St.

Frei handelbar: 72.22%

Leerverk. Aktien: -

Rückkaufquote: -0.37%

Mitarbeiter: 52

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Neutral

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 10.83

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -132.94%

Eigenkaprendite: -196.76%

>CYPHERPUNK Peer Group

Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung

>CYPHERPUNK Chart & Kurs - NASDAQ

>CYPHERPUNK News

16.03.26 - 21:54	Cypherpunk Reports Full Year 2025 Financial Results (PR Newswire)
	CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the year ended December 31, 2025. "2025 was a transformational year. Following a $58.88 million private placement led by Winklevoss Capital,......

09.03.26 - 14:21	Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL) (PR Newswire)
	Cypherpunk expands its holdings with new $5M investment in Zcash company, ZODL, alongside key investors including a16z, Winklevoss Capital, Coinbase, Paradigm, Chapter One, David Friedberg, Balaji Srinivasan, and others CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- Cypherpunk......

24.02.26 - 10:36	Bitcoin: "Womöglich haben wir in ein paar Monaten das nächste Rekordhoch" (Die Zeit)
	Es gibt gute Gründe, dass sich der Bitcoin-Kurs wieder erholt, sagt der Urvater der Technik, Adam Back. Wie der Cypherpunk den jüngsten Bitcoin-Einbruch erklärt....

22.01.26 - 13:12	Cypherpunk Adds Arjun Khemani as Strategic Advisor (PR Newswire)
	CAMBRIDGE, Mass., Jan. 22, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk"), the privacy technology company, today announced that Arjun Khemani has joined the company as a Strategic Advisor. Khemani, a prominent voice in the Zcash ecosystem and the......

08.01.26 - 15:54	Antanas Guoga: Antanas Guoga Announces Filing of Early Warning Report Related to Sol Strategies Inc. (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - January 8, 2026) - Antanas Guoga, Chair and director of Sol Strategies Inc. (formerly, Cypherpunk Holdings Inc., the "Company"), announces that he has filed an ......

12.11.25 - 14:02	Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results (PR Newswire)
	CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported......

20.10.25 - 13:03	Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 (PR Newswire)
	Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE,......

09.10.25 - 13:03	Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire)
	CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has closed its previously announced private placement led by Winklevoss Capital raising......

06.10.25 - 17:54	Leap Therapeutics: Aktie schießt nach 58,9-Mio.-Dollar-Investment um 82,2 % in die Höhe (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.10.25 - 15:39	Leap Therapeutics secures $58.9M PIPE to launch digital asset strategy; shares up 29% (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.09.25 - 13:03	Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 (PR Newswire)
	CAMBRIDGE, Mass., Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present the final clinical results from Part B of the DeFianCe study (NCT05480306), a......

14.08.25 - 14:00	Leap Therapeutics Slashes R&D Spending (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 13:27	Leap Therapeutics GAAP EPS of -$0.40 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 13:03	Leap Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
	CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated......

23.06.25 - 13:03	Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives (PR Newswire)
	Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder value CAMBRIDGE, Mass.,......

13.05.25 - 13:51	Leap Therapeutics GAAP EPS of -$0.37 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 13:06	Leap Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
	CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: Reported positive data from the......

25.04.25 - 19:03	Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting (PR Newswire)
	FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a......

15.04.25 - 13:03	Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer (PR Newswire)
	Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key......

26.03.25 - 12:30	Leap Therapeutics GAAP EPS of -$0.37 misses by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Illusionen sind eine Sache, die ein Mann gleichzeitig mit seinen Haaren und Zähnen verliert. - Franziska Friedl

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram